Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study

Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study

Abstract Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 recepto...

Full description

Bibliographic Details
Main Authors:	Jing Zhang, Yiqun Hao, Wuling Ou, Fei Ming, Gai Liang, Yu Qian, Qian Cai, Shuang Dong, Sheng Hu, Weida Wang, Shaozhong Wei
Format:	Article
Language:	English
Published:	BMC 2020-10-01
Series:	Journal of Translational Medicine
Subjects:	SARS-CoV-2 COVID-19 Interleukin-6 Tocilizumab
Online Access:	http://link.springer.com/article/10.1186/s12967-020-02571-x

Similar Items

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2010-05-01)

INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01)

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01)

Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19
by: Tatyana S. Kruglova, et al.
Published: (2021-11-01)

Development of type 1 diabetes in a patient treated with anti‐interleukin‐6 receptor antibody for rheumatoid arthritis
by: Eiji Kawasaki, et al.
Published: (2022-04-01)

Primary pathologic role of interleukin-6 in rheumatoid arthritis
by: G.L. Bajocchi, et al.
Published: (2013-05-01)

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
by: Athina Dimosiari, et al.
Published: (2023-02-01)

Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade
by: Mar Masiá, et al.
Published: (2022-08-01)

The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome
by: Luke Y.C. Chen, et al.
Published: (2021-05-01)

Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01)

Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy
by: Yoshihito Shima
Published: (2021-05-01)

Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
by: Steven Douedi, et al.
Published: (2020-01-01)

A serum interleukin-6-based analysis of patients with nasopharyngeal swab reverse-transcriptase polymerase chain reaction negative for SARS-COV-2 infection with CO-RADS 4 and 5 on computed tomography of the chest
by: K V Koti Reddy, et al.
Published: (2023-01-01)

Interleukin-6 and Macular Edema: A Review of Outcomes with Inhibition
by: Janine Yunfan Yang, et al.
Published: (2023-02-01)

Tratamiento con tocilizumab en el síndrome de dificultad respiratoria aguda del adulto asociado a SARS COV-2
by: Diego Bratta, et al.
Published: (2023-07-01)

Improvements in Intractable Lumbar and Lower-Extremity Symptoms after Systemic Administration of Tocilizumab, an Anti-interleukin-6 Receptor Antibody
by: Takeshi Sainoh, et al.
Published: (2022-02-01)

Successful Treatment of Recurrent Adult-Onset Still’s Disease with Tocilizumab: A Case Report and Literature Review
by: Zhong X, et al.
Published: (2023-11-01)

PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01)

Letter to the editor
by: Francisco José Fernández - Fernández, et al.
Published: (2012-01-01)

Tocilizumab In Severe To Critical Confirmed COVID-19: A Case Series At Ulin Referral Hospital Of South Kalimantan
by: Haryati Haryati, et al.
Published: (2021-06-01)

Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab
by: Jonathan P. Donnelly, et al.
Published: (2021-01-01)

Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers?
by: Aldo Venuti, et al.
Published: (2021-05-01)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
by: Robert Flisiak, et al.
Published: (2021-04-01)

Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial
by: Camilla Huse, et al.
Published: (2022-06-01)

Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
by: Pranay Sinha, et al.
Published: (2020-10-01)

Anti-interleukin-6 receptor therapy with tocilizumab for refractory pseudophakic cystoid macular edema
by: Brandon Huy Pham, et al.
Published: (2020-12-01)

Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?
by: Anca Cardoneanu, et al.
Published: (2022-01-01)

Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature
by: Hiroki Wakabayashi, et al.
Published: (2019-04-01)

Appropriate use of tocilizumab in COVID-19 infection
by: Şiran Keske, et al.
Published: (2020-10-01)

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review
by: Ju-Yang Jung, et al.
Published: (2018-12-01)

2020 Updates on tocilizumab indications for clinicians managing patients with severe acute respiratory syndrome coronavirus 2
by: Mohammed A Omair, et al.
Published: (2020-01-01)

Letter to the Editor in response to Chen et al. 2020
by: Jaya Ponnampalam, et al.
Published: (2020-11-01)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
by: Maxime Samson, et al.
Published: (2021-01-01)

Interleukin-6 inhibition in the management of non-infectious uveitis and beyond
by: Samendra Karkhur, et al.
Published: (2019-09-01)

Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study
by: Anna Olewicz-Gawlik, et al.
Published: (2021-12-01)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
by: Tariq Kewan, et al.
Published: (2020-07-01)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
by: Corrado Pelaia, et al.
Published: (2021-03-01)